This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lister, P. D.
Right arrow Articles by Sanders, C. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lister, P. D.
Right arrow Articles by Sanders, C. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Sep 1997, 1926-1932, Vol 41, No. 9
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Rationale behind high-dose amoxicillin therapy for acute otitis media due to penicillin-nonsusceptible pneumococci: support from in vitro pharmacodynamic studies

PD Lister, A Pong, SA Chartrand and CC Sanders
Center for Research in Anti-Infectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, Nebraska 68178, USA.

To evaluate whether increased doses of amoxicillin should be used to treat acute pneumococcal otitis media, an in vitro pharmacokinetic model was used to evaluate the killing of pneumococci by amoxicillin when middle ear pharmacokinetics were simulated. Logarithmic-phase cultures were exposed to peak concentrations of 3, 6, and 9 microg of amoxicillin per ml every 12 h, and an elimination half-life of 1.6 h was simulated. Changes in viable bacterial counts were measured over 36 h. All three doses rapidly decreased the viable bacterial counts of penicillin-susceptible strains below the 10-CFU/ml limit of detection by 6 to 10 h and maintained counts below this limit through 36 h. The 3- microg/ml peak dose was much less effective against two of three strains with intermediate penicillin resistance and all three penicillin-resistant strains, with bacterial counts approaching those in drug-free control cultures by 12 h. The 6-microg/ml peak dose completely eliminated two of three strains with intermediate penicillin resistance and maintained viable counts of the other nonsusceptible strains at 1.5 to 2 logs below the initial inoculum through 36 h. The 9- microg/ml peak dose was most effective, completely eliminating all three strains with intermediate penicillin resistance and maintaining the viable counts of the resistant strains at 3 to 4 logs below the original inoculum. The pharmacodynamics observed in this study suggest that peak concentrations of amoxicillin of 6 to 9 microg/ml may be sufficient for the elimination of penicillin-nonsusceptible pneumococcal strains causing otitis media, especially those with intermediate resistance to amoxicillin. In vivo pharmacokinetic studies are needed to determine if these levels can be achieved in middle ear fluid with amoxicillin at 70 to 90 mg/kg/day divided into two daily doses. If these levels are reliably achieved, then clinical studies are warranted.


This article has been cited by other articles:

  • Garbutt, J., Rosenbloom, I., Wu, J., Storch, G. A. (2006). Empiric first-line antibiotic treatment of acute otitis in the era of the heptavalent pneumococcal conjugate vaccine.. Pediatrics 117: e1087-e1094 [Abstract] [Full Text]  
  • Garbutt, J., St. Geme, J. W. III, May, A., Storch, G. A., Shackelford, P. G. (2004). Developing Community-Specific Recommendations for First-Line Treatment of Acute Otitis Media: Is High-Dose Amoxicillin Necessary?. Pediatrics 114: 342-347 [Abstract] [Full Text]  
  • O'Brien, K. L., Santosham, M. (2004). Potential Impact of Conjugate Pneumococcal Vaccines on Pediatric Pneumococcal Diseases. Am J Epidemiol 159: 634-644 [Abstract] [Full Text]  
  • Garrison, G. D., Sorum, P. C, Hioe, W., Miller, M. M (2004). High-Dose Versus Standard-Dose Amoxicillin for Acute Otitis Media. The Annals of Pharmacotherapy 38: 15-19 [Abstract] [Full Text]  
  • Gustafsson, I., Lowdin, E., Odenholt, I., Cars, O. (2001). Pharmacokinetic and Pharmacodynamic Parameters for Antimicrobial Effects of Cefotaxime and Amoxicillin in an In Vitro Kinetic Model. Antimicrob. Agents Chemother. 45: 2436-2440 [Abstract] [Full Text]  
  • Lister, P. D., Sanders, C. C. (1999). Pharmacodynamics of Trovafloxacin, Ofloxacin, and Ciprofloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model. Antimicrob. Agents Chemother. 43: 1118-1123 [Abstract] [Full Text]  
  • Woodnutt, G., Berry, V. (1999). Efficacy of High-Dose Amoxicillin-Clavulanate against Experimental Respiratory Tract Infections Caused by Strains of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43: 35-40 [Abstract] [Full Text]  
  • Lister, P. D., Sanders, C. C. (1999). Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 43: 79-86 [Abstract] [Full Text]  
  • Block, S. L. (1999). Strategies for Dealing With Amoxicillin Failure in Acute Otitis Media. Arch Fam Med 8: 68-78 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»